Ra Pharmaceuticals Announces Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia Gravis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. META

Go back to Ra Pharmaceuticals Announces Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia Gravis

Ra Pharma (RARX) PT Raised to $35 at SunTrust Robinson Humphrey

December 10, 2018 12:35 PM EST

SunTrust Robinson Humphrey analyst Edward Nash raised the price target on Ra Pharma (NASDAQ: RARX) to $35.00 (from $28.00) while maintaining a Buy rating.

Nash commented, "Ra Pharma reported positive top-line results from a Phase II zilucoplan trial in gMG. 0.3mg/kg zilucoplan cohort achieved a... More